Resveratrol for Endothelial Dysfunction and Metabolic Control in Type 2 Diabetes

Type 2 diabetes mellitus is associated with endothelial dysfunction, which contributes to increased cardiovascular risk. Chronic hyperglycemia induces oxidative stress and reduces nitric oxide bioavailability, leading to impaired endothelial function. Resveratrol, a natural polyphenol with antioxidant and anti-inflammatory properties, has been shown to improve endothelial function in experimental studies. This randomized controlled trial aims to evaluate the effectiveness of resveratrol supplementation in improving endothelial dysfunction and metabolic control in patients with type 2 diabetes mellitus. Endothelial function will be assessed using flow-mediated dilatation (FMD) of the brachial artery and serum endothelial nitric oxide synthase (eNOS) levels. Metabolic parameters including fasting blood glucose, postprandial glucose, HbA1c, and lipid profile will also be evaluated.

NCT Number	NCT07569744
Lead Sponsor	Universitas Sriwijaya
Conditions	Type 2 Diabetes Mellitus, Endothelial Dysfunction
Enrollment	48 participants
Start Date	2026-05-01
Primary Completion	2026-06-01 (estimated)
Study Completion	2026-06-10 (estimated)
Updated on ClinicalTrials.gov	2026-06-16